Projected most valuable R&D projects based on net present value 2022

Published by
Matej Mikulic,
Jan 18, 2023
This statistic displays the top pharmaceutical R&D projects based on net present value, as of December 2022. According to the source, the top R&D project was Daiichi Sankyos' monoclonal antibody for lung cancer treatment Datopotamab deruxtecan with a net present value of nearly 10 billion U.S. dollars at that time.

Selected top pharmaceutical R&D projects based on net present value (NPV) as of December 2022 (in billion U.S. dollars)

Loading statistic...

© Statista 2023
You need to log in to download this statistic
Register for free
Already a member?
Log in
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

December 2022

Region

Worldwide

Survey time period

as of December 2022

Citation formats
Statista Accounts: Access All Statistics. Starting from $468 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 USD $39 USD / Month *
in the first 12 months
Professional Account
Full access

Corporate solution including all features.

* Prices do not include sales tax.

Statistics on " Top pharmaceutical drugs "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Statistics on Top pharmaceutical drugs

Global overview

4

Top companies' top products

5

Best-selling drugs

8

U.S. overview

4

Outlook

5

Further related statistics

19

Further Content: You might find this interesting as well

Statistics

Topics

Pharmaceutical research and development (R&D)Global pharmaceutical industryPharmaceutical industry in the U.S.Top pharmaceutical drugsCoronavirus (COVID-19) vaccines and treatments
Statista Accounts: Access All Statistics. Starting from $468 USD / Year
Learn more about how Statista can support your business.
Menu